New study confirms effectiveness of BCM-95 to treat colitis, says Arjuna - Pharmaceutical Technology

Indian pharmaceutical company Arjuna has announced that a new study has confirmed BCM-95, a high-potency turmeric extract, is more effective than standard curcumin in reducing the disease activity and inflammatory burden of colitis.

The study was published in the journal ‘Scientific Reports’ this month by Shusuke Toden of Baylor University, Dallas, Texas.

The study compared the anti-inflammatory efficacy of standard curcumin and BCM-95 in a well-recognised, imposed animal model of colitis.

The results found that BCM-95, which is composed of essential oil with curcuminoids, performed better than the standard curcumin in reducing the disease activity and inflammatory burden in the model.

The greater therapeutic efficiency of BCM-95 over standard curcumin in colitis was attributed to properties beyond enhanced bioavailability, including synergism between ingredients in this branded composition.

Arjuna joint managing director Benny Antony said: "For the first time, the enhanced bioactivity of BCM-95 as a result of synergism has been confirmed.

"This new finding provides our customers an added value for promoting their BCM-95-based formulations in an increasingly crowded curcumin market."

"This new finding provides our customers an added value for promoting their BCM-95-based formulations in an increasingly crowded curcumin market."

Developed in joint venture with Dolcas Biotech, BCM-95 is a proprietary formulation of Arjunanatural extracts without any synthetic additives.

The company noted that BCM-95 has been extensively researched in multiple clinical studies by universities throughout the US, Japan, Australia and India with 13 international patents.

Dolcas Biotech markets the product in the US.

Since the ingredient’s debut 15 years ago, both companies have campaigned around the notion of synergism in turmeric constituents, which has been previously confirmed in the case of enhancing bioavailability